---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088340"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:00:21.185741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunome reports Q2 2024 net loss of $36.1M; cash $278.4M, runway into 2026

## Summary
- Cash, equivalents and marketable securities totaled $278.4M; expected runway into 2026.
- Net loss of $36.1M for Q2 2024; R&D expense $29.1M, G&A $7.0M.
- Phase 3 RINGSIDE Part B (AL102) for desmoid tumors fully enrolled; topline data expected H2 2025.
- IND submissions for IM-1021 and IM-3050 anticipated in Q1 2025.
- Business development transactions with Atreca, Nectin Therapeutics, Bluefin, OncoResponse expanding ADC toolbox.

## SEC filing metadata
- accession: 0001104659-24-088340
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924088340/0001104659-24-088340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924088340/tm2421310d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088340
- JSON: https://secwatch.observer/filing/0001104659-24-088340.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.